This is a prospective study to evaluate the safety and efficacy of Sintilimab (PD-1 antibody) in sequential combination with Peg-IFNα-2b in NA-supressed CHB patients who had previously received Peg-IFNα therapy.

开始日期2024-06-15

申办/合作机构-

ChiCTR2300074909

/ Recruiting临床1期IIT

Evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of nebulized inhalation of pegylated interferon alpha-2b injection in healthy adult subjects

开始日期2023-08-10

申办/合作机构-

CTRI/2020/12/029855

/ Active, not recruiting临床3期

A Phase III, Randomized, Controlled, Open-Label Studyto Evaluate the Efficacy and Safety of PegylatedInterferon Alfa-2b In the Treatment of Adult PatientsDiagnosed With SARS-CoV-2 (COVID-19).

开始日期2020-12-17

申办/合作机构-

100 项与聚乙二醇干扰素α-2b生物类似药(Zydus Cadila Healthcare Ltd.) 相关的临床结果

登录后查看更多信息

100 项与聚乙二醇干扰素α-2b生物类似药(Zydus Cadila Healthcare Ltd.) 相关的转化医学

登录后查看更多信息

100 项与聚乙二醇干扰素α-2b生物类似药(Zydus Cadila Healthcare Ltd.) 相关的专利（医药）

登录后查看更多信息

439

项与聚乙二醇干扰素α-2b生物类似药(Zydus Cadila Healthcare Ltd.) 相关的文献（医药）

2025-12-01·Journal of Virus Eradication

Efficacy and predictors of pegylated-interferon in hepatitis B surface antigen seroclearance in immune active and inactive chronic hepatitis B patients

Article

作者: Han, Chao ; Zhu, Mujia ; Liu, Zhihong ; Zhang, Xiaoyong ; Li, Guiping ; Jin, Linlin ; Qin, Qiuying

Background and objectives:

Pegylated interferon (PegIFN) is one of the few strategies capable of achieving hepatitis B surface antigen (HBsAg) seroclearance in chronic hepatitis B (CHB) patients. However, its role in HBeAg-negative chronic HBV infection (also referred to as immune-inactive or "inactive carrier" phase) remains unclear. This study compared PegIFN efficacy between immune-inactive and immune-active patients and explored predictors of treatment response.

Research methods:

We retrospectively analyzed 211 consecutive HBeAg-negative patients treated with PegIFN α-2b in our center from 2019 to 2023, including 139 with immune-inactive chronic HBV infection and 72 immune-active CHB patients. Effectiveness was assessed in the full analysis set (FAS) and efficacy in the per-protocol set (PPS). Predictors of HBsAg seroclearance were identified using Cox regression.

Results:

At week 48, overall HBsAg seroclearance was 26.5 % (FAS), with comparable outcomes between immune-inactive and immune-active groups (26.6 % vs. 26.4 %, P > 0.05). Inactive patients receiving PegIFN + nucleos(t)ide analogues (NAs) showed no added benefit. In the PPS, clearance reached 69.1 %, but 40.3 % discontinued prematurely-mostly due to subjective intolerance-highlighting a major gap between real-world effectiveness and theoretical efficacy. Multivariate analysis identified two independent predictors: baseline HBsAg <100 IU/mL (HR 2.999, 95 % CI 1.625-5.536, P < 0.001) and on-treatment HBsAg decline ≥1 log₁₀ IU/mL within any 12-week interval (HR 11.205, 95 % CI 4.379-28.674, P < 0.001).

Conclusions:

PegIFN α-2b achieved clinically meaningful HBsAg seroclearance in both immune-inactive and immune-active patients. Early discontinuation markedly reduced real-world effectiveness. Baseline low HBsAg and dynamic on-treatment decline are pragmatic predictors for optimizing patient selection and guiding interferon-based strategies.

2025-11-01·ALIMENTARY PHARMACOLOGY & THERAPEUTICS

High‐Throughput Viral Integration Detection Reveals Baseline Breakpoints Burden Associated With HBsAg Seroclearance

Article

作者: You, Jie ; Huang, Fei ; Wang, Peng ; Wang, Xiaojing ; Yan, Weiming ; Chen, Tao ; Wu, Qianjun ; Xi, Dong ; Wu, Di ; Ning, Qin ; Han, Meifang ; Wu, Wenyu ; Zhang, Yixuan ; Gu, Misi

ABSTRACT:

Background:

The profiles of hepatitis B virus (HBV) integration related to hepatitis B surface antigen (HBsAg) loss remain largely unknown.

Aims:

We aimed to delineate the patterns of HBV integration in virally suppressed chronic hepatitis B (CHB) patients and their association with HBsAg loss following antiviral therapy.

Methods:

Forty‐five patients with paired liver biopsies were randomly selected from the Anchor study for high‐throughput viral integration detection. The primary endpoint was HBsAg loss at Week 96. In Group II (pegylated interferon alpha‐2b & entecavir), 13 patients achieved HBsAg loss, whereas all patients in Group I (entecavir monotherapy) and 17 in Group II failed to achieve HBsAg loss.

Results:

At baseline, the level of clonal expansion was positively correlated with the duration of nucleos(t)ide analogue (NUC) treatment, the alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels, whereas no association was observed with the HBsAg, hepatitis B core‐related antigen (HBcrAg), HBV RNA or covalently closed circular DNA (cccDNA) levels. Patients with less than 28 breakpoint types achieved a significantly higher rate of HBsAg loss following Peg‐IFN‐based therapy at Week 48 and 96, compared to those with more than 28.

Conclusions:

The duration of NUC treatment, as well as ALT and AST levels, were associated with the level of clonal expansion in virally‐suppressed patients. A lower number of breakpoint types at baseline may be related to a higher HBsAg loss rate following Peg‐IFN‐based treatment and serve as a useful marker in guiding treatment decision‐making (NCT02327416).

Trial Registration:

The Anchor study is registered at ClinicalTrials.gov, NCT02327416

2025-10-07·Microbiology Spectrum

Predictive value of hepatic, hematological, and immunological markers and their temporal dynamics in chronic hepatitis B functional cure

Article

作者: Zheng, Caixia ; Zeng, Jianyong ; Xue, Xiulan ; Zheng, Yincheng

ABSTRACT:

Hepatitis B virus (HBV) infection remains a major global health burden. While interferon-alpha (IFNα) therapy demonstrates antiviral and immunomodulatory effects, reliable prognostic markers for sustained response are needed. Transaminases, hematological parameters, and cytokines may serve as potential predictors, but their dynamic changes during IFNα therapy remain poorly characterized. In this prospective real-world study, 181 chronic HBV (CHB) patients received weekly PEG-IFNα-2b for 48 weeks, with serial assessments of virological (HBV DNA, hepatitis B surface antigen [HBsAg]), biochemical (alanine aminotransferase [ALT], aspartate aminotransferase [AST]), hematological (white blood cell [WBC], platelets), and cytokine (interleukin [IL]-4/6, tumor necrosis factor-alpha [TNF-α], IFN-γ) profiles every 4 weeks. The primary outcome was functional cure of CHB. Statistical analyses included (i) generalized linear models (GLMs) evaluating associations between cure status and predictor trends; (ii) Cox regression identifying prognostic factors; (iii) trajectory clustering of biomarker dynamics. Results indicated that sustained declines in ALT (β = −0.025, P = 0.029) and AST (β = −0.033, P = 0.039) were predictive of functional cure, as confirmed by Cox models (ALT HR = 1.003, P = 0.002; AST HR = 1.004, P = 0.013). Additionally, the maximum monthly increase in WBC was independently associated with functional cure (β = 0.380, P = 0.009). Elevated baseline IL-4 (HR = 1.144, P < 0.001) and longitudinal changes in IL-4/IFN-γ also predicted functional cure ( P < 0.05), although the inclusion of cytokines did not enhance model performance. Trajectory analysis further identified distinct patterns of ALT, AST, and hematological parameter changes linked to functional cure. In conclusion, ALT and AST remain robust predictors of the functional cure of CHB following IFNα therapy, while dynamic WBC and cytokine profiles provide supplementary prognostic value.

IMPORTANCE:

Interferon-alpha (IFNα) therapy, known for its antiviral and immunomodulatory effects, lacks reliable predictors of functional treatment response. This study addresses this gap by systematically analyzing dynamic changes in biochemical, hematological, and immunological markers during IFNα therapy. The findings validate alanine aminotransferase (ALT) and aspartate aminotransferase (AST) as robust predictors for functional cure of chronic Hepatitis B virus (CHB), while highlighting the complementary prognostic value of within-visit fluctuations in white blood cell (WBC) counts and cytokine profiles, particularly IL-4 and IFN-γ. Furthermore, the study identifies longitudinal stability in ALT and AST levels, along with specific hematological patterns characterized by initial decline followed by gradual recovery, as predictors of functional cure. By employing generalized linear models, Cox regression, and trajectory clustering, this research provides a comprehensive framework for understanding functional treatment response dynamics of CHB. These findings are significant for clinicians and researchers aiming to refine therapeutic strategies and achieve better patient outcomes in CHB.

项与聚乙二醇干扰素α-2b生物类似药(Zydus Cadila Healthcare Ltd.) 相关的新闻（医药）

2025-09-19

·PRNewswire

AusperBio Completes Enrollment in Two Phase II Clinical Trials of AHB-137 for Chronic Hepatitis B

SAN FRANCISCO, Sept. 18, 2025 /PRNewswire/ -- AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (collectively AusperBio), a clinical-stage biotechnology company advancing targeted oligonucleotide therapies for chronic hepatitis B (CHB) functional cure, today announced the completion of patient enrollment in two Phase II clinical trials evaluating its lead candidate, AHB-137, in patients with chronic hepatitis B ( CHB), marking an important milestone in the clinical development program. The Phase II study AB-10-8007 (NCT07069569) is a randomized, open-label, multicenter study to evaluate the efficacy and safety of AHB-137 Injection in combination with either a hepatitis B vaccine or pegylated interferon α-2b (Peg-IFN) in participants with HBeAg-negative CHB receiving nucleos(t)ide analogue (NA) therapy. The Phase II study AB-10-8008 (NCT06829329) is a randomized, multicenter study to evaluate the efficacy and safety of AHB-137 Injection in treatment-naïve participants with CHB. "Combination therapies have historically been a key to treat or cure chronic viral infections, including HIV and HCV." said Dr. Guofeng Cheng, Co-founder and CEO of AusperBio. "The AB-10-8007 study aims to combine AHB-137 with approved HBV treatments to further increase functional cure rates, while the AB-10-8008 study explores the potential to expand AHB-137 treatment to a broader patient population. Together, these studies could further establish AHB-137 as the potential backbone therapy for HBV functional cure. We look forward to sharing interim results at international conferences throughout 2026." "We are deeply grateful to the patients, investigators, site teams, and our AusperBio colleagues for their dedication and contributions to reaching this important milestone," said Dr. Chris Yang, Co-founder and CSO of AusperBio. "The completion of enrollment in these Phase II trials positions us well as we move into the pivotal Phase III study of AHB-137, which was recently approved in China. We are excited and committed to advancing new treatment options with the goal of bringing a functional cure to a broader population of patients living with HBV." About AHB-137 AHB-137, a novel unconjugated antisense oligonucleotide ( ASO) designed using AusperBio's proprietary Med-Oligo™ ASO technology platform and an investigational medicine, is being developed to achieve a functional cure for chronic hepatitis B. Its clinical development has generated promising data, with key preclinical and clinical results presented at global leading conferences including EASL (2023, 2024, 2025), AASLD (2024), and APASL (2025). This novel dual-mechanism ASO has completed its global Phase 1 trial and is currently advancing through multiple Phase 2 trials and a phase 3 trial in China. Supported by a clear global development strategy, AHB-137 is progressing rapidly toward delivering a potential cure for HBV. About AusperBio. AusperBio is a clinical-stage biopharmaceutical company with operations in the USA and China, dedicated to advancing oligonucleotide and targeted delivery technologies for transformative therapies, with an initial focus on achieving functional cure for chronic hepatitis B infection. The company has developed a proprietary Med-Oligo™ ASO platform which has been shown to substantially enhance the current ASO therapeutics, through novel insights into ASO design. Combining with efficient targeted delivery conjugation technologies, the modular Med-Oligo™ Platform empowers ASO therapeutics to treat a broad range of diseases, including viral infections, metabolic conditions, genetic disorders, and immune diseases. For further information, please contact: Media Contact Email: [email protected] Investor Relations Contact: Tel: 650-888-1756 (US) Email: [email protected] SOURCE AusperBio Therapeutics Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床2期寡核苷酸临床3期临床1期疫苗

2023-04-07

·CPHI制药在线

研发 | 干扰素抗病毒作用机制及其在疾病治疗中的应用

关注并星标CPHI制药在线干扰素（interferon IFN）是一类重要的细胞因子，能直接参与上皮细胞的抗病毒免疫反应，介导天然免疫应答诱导 IFN 刺激基因（interferon stimulated gene，ISG）的表达，从而使机体快速建立针对病毒侵染的天然免疫防线。根据干扰素结构特点，结合受体和生物活性，人干扰素可分为3类，即Ⅰ、Ⅱ和Ⅲ型干扰素，其基因分别位于人9p21-22、12q24.1和19q13.13 染色体。在人类三种类型的干扰素中，Ⅰ型干扰素主要包括 IFN-α，IFN-β等20种亚型，Ⅱ型干扰素只有 IFN-γ，Ⅲ型干扰素包括 IL-29 ( IFN-λ1) 等 4 种亚型。大多数被病毒感染的细胞都可以产生Ⅰ型干扰素，分泌的 IFN-α/β 可与邻近未被感染的细胞上的共同受体结合并启动旁分泌信号级联反应。Ⅰ型和Ⅲ型干扰素被认为是经典的抗病毒干扰素，α 型干扰素是临床治疗抗病毒的主要亚型，主要分为α-1b、α-2b、α-2a 等亚型。近期研究表明，Ⅲ型干扰素与黏膜免疫有重要的关系，而IFN-γ 也具有良好的病毒抑制特性。干扰素抗病毒作用机制干扰素激活分子在病毒复制周期的许多阶段表现出抗病毒活性，包括病毒进入、转录、RNA 稳定性、翻译、成熟和释放等阶段。这种作用是在抗病毒基因表达的调节下进行的。 ①病毒的附着和进入。HPSE 是一种编码乙酰肝素酶的干扰素诱导基因（ISG），HPSE 的异位表达可广泛抑制甲病毒、黄病毒、副粘病毒和诺如病毒。病毒进入是多个ISG 靶向的阶段，IFITM 蛋白质是经典的 ISG，可破坏多种包膜病毒的进入，IFITM 蛋白将病毒颗粒运输到降解溶酶体中，可有效地阻止病毒的进入。CH25H 是一种干扰素诱导酶，可将胆固醇转化为25-羟基胆固醇(25-HC)，25-HC 膜扰动功能抑制病毒进入。最近发现的靶向病毒进入的 ISG人类核受体辅激活因子 7 ( NCOA7) 可以结合液泡H + -ATP 酶，促进囊泡酸化和内吞物的降解，从而抑制通过内吞作用进入细胞的多种病毒的感染。此外，在病毒基因表达开始之前的进入后病毒过程也可以被 ISG 干扰，以及某些ISG 还能特异性地阻断病毒通过核孔复合体。 ②病毒基因组的扩增。IFI16是一种 IFN 诱导的 DNA 传感器，被证明可以干扰人类巨细胞病毒基因的转录。RBBP6 是一种泛素E3 连接酶，RBBP6可直接与埃博拉病毒 VP30 蛋白相互作用，从而阻止VP30与病毒NP 蛋白的相互作用并干扰病毒转录。干扰素能强烈诱导2-5A 寡合成酶/核糖核酸酶L系统，核糖核酸酶L被双链 RNA 激活可降解所有单链 RNA，从而抑制病毒复制。 ③病毒蛋白质的翻译。在病毒复制周期中，干扰素通过多种机制靶向病毒蛋白翻译。干扰素通过PKR 基因启动子中的 ISRE 和 GAS 刺激蛋白激酶 R( protein kinase R，PKR) 的表达，进而将翻译起始因子 eIF2-α 的51位Ser 磷酸化。eIF2-α-GTP 是启动病毒翻译所必需的。eIF-2B从每轮翻译起始后回收 eIF2-α-GDP，进行鸟嘌呤核苷酸交换，产生eIF2-α-GTP。然而，eIF-2B优先与 eIF2-α 的磷酸化形式结合。因此，eIF-2B 的细胞储备被隔离在非活性复合物 eIF2α-GDP-eIF-2B中，从而快速抑制病毒蛋白的翻译。此外，PKR 还通过调节 STAT1 的丝氨酸磷酸化和 IκB 的磷酸化，从而激活NF-κB 依赖性基因，在细胞增殖、肿瘤抑制和信号转导中发挥作用。IFIT 家族(包括人类的 IFIT1、IFIT2、IFIT3和IFIT5) 利用多种机制靶向病毒蛋白的产生，如结合 eiF3C 或 eiF3E 以抑制翻译起始。 ④病毒颗粒的组装和释放。病毒复制周期的后期包括病毒粒子组装、运输和从细胞中释放。与病毒复制周期的早期阶段相比，针对这些步骤的 ISG较少。Tetherin 是一种跨膜蛋白，可以将萌芽病毒粒子锚定到细胞表面并阻止它们释放。CNP( 2-环核苷酸-3-磷酸二酯酶) 结合Gag 并抑制 HIV-1颗粒组装。鸟苷酸结合蛋白 5( GBP5) 阻碍病毒包膜糖蛋白组装病毒粒子。另外，Ⅰ型干扰素作为抗病毒细胞因子发挥作用。IFN-α 激活 NK 细胞，进而破坏病毒和其他靶细胞，增加 B 细胞的增殖，B 细胞分泌抗病原体的抗体，通过上调表面细胞MHCⅠ类分子的表达，增强CD8+T 细胞的反应。Ⅰ型干扰素还上调 IL-12Rb，增加 MHC Ⅱ类分子的表达。IFNα-1b 可以增加单核细胞 MHCⅡ抗原的表达。炎症性干扰素信号促进和调节巨噬细胞和树突状细胞的发育、成熟和刺激能力。这些效应促进抗病毒抗体的产生，限制病毒复制以限制系统性病毒持续性。干扰素在疾病治疗中的应用自从干扰素产品在我国上市以来，获批的治疗适应症已扩大到几十种疾病，主要包括治疗病毒性疾病和肿瘤。干扰素在治疗皮肤科疾病方面也已得到广泛应用，包括带状疱疹、生殖器疱疹，尖锐湿疣、寻常疣、扁平疣和皮肤肿瘤等。此外，干扰素在抗炎症反应以及维持机体生理动态平衡方面也发挥着重要作用。 ①皮肤科疾病。2021年《中国尖锐湿疣临床诊疗指南》强烈推荐皮损内注射干扰素，证据等级为A ，2020 年欧洲皮肤病与性病学会发布了《生殖器传染性软疣管理指南》，将干扰素作为免疫抑制剂，2019 年《带状疱疹临床路径》中推荐干扰素作为免疫增强剂，2018 年德国颁布的《HPV 感染及其相关病变的诊疗指南》中将 IFN-α(局部用或病灶内用药)作为首选治疗方案之一。2014 年发布的《英国肛门-生殖器疱疹指南》提及有证据显示三氟胸苷单独或联合 IFN-α 可以治疗耐受性生殖器疱疹。并且，根据现有临床试验来看，IFN-α 也在实际临床应用中显示出了很好的效果。 ②抗病毒药物和免疫调节。作为广谱抗病毒药物和免疫调节剂，干扰素在临床上早已广泛用于治疗各种儿童病毒性疾病，《重组人干扰素α1b 在儿科应用的专家共识》，《手足口病诊疗指南》和《α干扰素在儿科临床合理应用专家共识》等众多指南共识明确阐明干扰素可用于小儿病毒性肺炎、手足口病、疱疹性咽峡炎和毛细支气管炎等。 ③肝病治疗。α-干扰素是治疗慢性活动性乙型肝炎的首选药物，2019 年《中国慢性乙型肝炎防治指南》推荐 PEG-IFN-α 和 IFN-α用于治疗慢性乙型肝炎。干扰素也是治疗丙型肝炎的有效药物之一，可抑制急性丙型肝炎转化为慢性丙型肝炎。 ④治疗SARS-CoV-2。干扰素吸入给药能够以更小的剂量实现高气道暴露，快速达到肺部起效浓度，减少全身副作用。我国国家卫生健康委员会发布的多版《新型冠状病毒肺炎诊疗方案》中均提出可用 IFN-α 雾化吸入进行抗病毒治疗，在新冠肺炎诊疗方案试行第八版中阐明抗病毒治疗可单独用 IFN-α，成人每次500万U或相当剂量，加入灭菌注射用水 2mL，2次/d，雾化吸入，疗程不超过 10 d。此外，IFN-α 还可与利巴韦林联合应用。此外，干扰素能够通过抗细胞增殖，免疫调节和抑制肿瘤血管形成等方式对肿瘤生长起到抑制作用，临床主要用来治疗白血病、淋巴瘤、Kaposi肉瘤，黑色素瘤、肾癌、多发性骨髓瘤等。干扰素也可用于治疗多发性硬化症等自身免疫性疾病。干扰素是我国第一个投放市场的基因工程药物，自1986年美国FDA及1989 年我国SFDA 批准投放市场以来，干扰素的治疗适应症逐年扩大，目前国际上批准的治疗适应证已有数十种，取得了重要的社会效益和良好的经济效益。作为机体免疫调节和抗病毒物质，干扰素一直受到人们的关注，干扰素的基础和临床研究已取得了较大进展。根据国家药品监督管理局网站公示，我国目前批准干扰素相关产品有92个，型别包括 α-1b、α-2a、α-2b和 γ，以及长效干扰素 PEG-IFN-α2b。剂型包括注射液、滴眼液、阴道泡腾片、乳膏、软膏、凝胶、喷雾剂和栓剂。PEG-IFN-α2a、PEG-IFN-α2b、IFNα-1b、IFNα-2a 和 IFNα-2b 等已进入了 2020 版国家医保目录，这一举措显著降低了老百姓的看病成本，切实保障了人民健康。参考资料 [1]郑丽舒,段招军,罗迪贤,陈宏翔,邓启文,侯云德.干扰素的发展历史、现状与展望[J].皮肤科学通报,2021,38(06):479-484+1. [2]庞立丽,段招军,罗迪贤,陈宏翔,邓启文,侯云德.干扰素作用机制的研究进展[J].皮肤科学通报,2021,38(06):485-491+2. [3]金丽,苏强,周建华,马忠仁.Ⅰ型和Ⅲ型干扰素抗病毒作用机制的研究进展[J].中国生物制品学杂志,2021,34(04):481-486. 智药研习社近期课程报名来源：CPHI制药在线声明：本文仅代表作者观点，并不代表制药在线立场。本网站内容仅出于传递更多信息之目的。如需转载，请务必注明文章来源和作者。投稿邮箱：Kelly.Xiao@imsinoexpo.com▼更多制药资讯，请关注CPHI制药在线▼点击阅读原文，进入智药研习社~

100 项与聚乙二醇干扰素α-2b生物类似药(Zydus Cadila Healthcare Ltd.) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	L03AB10	-

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
尖锐湿疣	日本	Zydus Cadila Healthcare Ltd.	2014-01-01
乙型肝炎	日本	Zydus Cadila Healthcare Ltd.	2014-01-01
丙型肝炎	日本	Zydus Cadila Healthcare Ltd.	2014-01-01

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
新型冠状病毒感染	临床2期	墨西哥	Zydus Lifesciences Ltd.	2020-08-11

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


PB2730 (EHA2025)	N/A	慢性期慢性髓性白血病	17	PEG IFNα-2b + TKI	醖積餘選獵簾襯鬱鬱構(餘築構憲築蓋蓋膚齋窪) = 築獵鬱網鏇襯膚鹽築鹽衊襯壓鬱築構構鑰鏇鹹 (夢壓構憲鹽積鏇艱餘遞 ) 更多	积极	2025-05-14
EHA2024	N/A	真性红细胞增多症 \| 原发性血小板增多症	81	Peg-IFN-α-2b	鹽窪簾構選築遞選蓋鏇(夢鹹膚繭淵鹽鏇構窪範) = 網夢衊鏇鏇廠鏇製艱廠願衊願積繭遞壓獵鹽餘 (製憲淵壓鏇糧鬱齋鹽廠 )	积极	2024-05-14
Pubmed \| J Clin Gastroenterol	临床3期	丙型肝炎	125	Peginterferon-α-2b plus Ribavirin	選網繭淵繭糧窪蓋襯繭(淵壓壓繭構餘鹹夢餘願) = 願網齋製醖獵膚簾艱憲醖齋構網齋遞觸獵築廠 (糧壓衊鑰餘壓壓鏇遞選 ) 更多	-	2012-09-01
Pubmed \| Clin Genitourin Cancer	临床2期	晚期肾细胞癌	32	Pegylated IFN-alpha 2b	襯淵壓窪蓋願構範築築(獵獵鑰積醖鏇繭築鏇艱) = 遞膚網築觸願壓壓鏇憲襯繭鹽獵壓願獵製製窪 (積觸衊鹹簾蓋積鑰遞鹽, 18 ~ not reached) 更多	-	2008-03-01